生命科学资讯

A 2-speed payer transformation is underway

CHMP calls to reject Anavex's Alzheimer’s pill over impurities, side effects and weak efficacy

#SABCS25: Celcuity further details Phase 3 win; Relay’s PI3Kα inhibitor’s consistent performance; and more

Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancers

Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor

GSK spins out corporate VC fund focused on bioelectronic tech

Tenaya targets $60M offering after heart disease pipeline updates

FDA broadens label for Amgen's Uplizna as it enters rare disease competition

CDC report underscores benefit of Covid-19 vaccines in kids

Geron cuts one-third of staff, focusing on turning Rytelo launch around

EU forges deal over major pharma legislative changes

GSK's new antibiotic wins gonorrhea approval

Top Trump lawyer calls on SCOTUS to reverse 'skinny' generic drug label decision

Umoja delays first readout for in vivo CAR-T therapy

Rezolute crashes as its only drug fails in Phase 3

Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial

AC Immune says early biomarker data are promising in Parkinson's, but clinical benefit remains unclear

Corbus’ obesity pill posts muted weight loss data; Disco adds another €16M in seed funding

Health tech investors are getting creative with exits

Zealand inks deal with OTR Therapeutics as it spells out broader metabolic disease ambitions